These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 10848067

  • 1. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [Abstract] [Full Text] [Related]

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 3. Nelfinavir is number 4 -- but should it bat cleanup, or lead off?
    Mascolini M.
    J Int Assoc Physicians AIDS Care; 1997 Jun; 3(6):17-21. PubMed ID: 11364427
    [Abstract] [Full Text] [Related]

  • 4. A patient's guide to protease inhibitors.
    Elperin A, Sax P.
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [Abstract] [Full Text] [Related]

  • 5. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E, Dreezen C, Desmet P, Smets E, Fransen K, Vandercam B, Pelgrom J, Clumeck N, Colebunder R.
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, Study Team.
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [Abstract] [Full Text] [Related]

  • 7. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA.
    J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Losso M, Peters B, Obel N, Castagna A, Dragsted UB, Lundgren JD, MaxCmin1 and 2 trial groups.
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [Abstract] [Full Text] [Related]

  • 9. Update on HIV protease inhibitors.
    Vella S.
    AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
    [Abstract] [Full Text] [Related]

  • 10. Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.
    Lichterfeld M, Wöhrmann A, Schmeisser N, Fätkenheuer G, Salzberger B, Wyen C, Schmitz K, Sauerbruch T, Rockstroh JK.
    Eur J Med Res; 2003 Feb 21; 8(2):56-60. PubMed ID: 12626282
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
    Salzberger B, Rockstroh J, Wieland U, Franzen C, Schwenk A, Jütte A, Hegener P, Cornely O, Mörchen C, Gaensicke T, Diehl V, Fätkenheuer G.
    Eur J Med Res; 1999 Nov 22; 4(11):449-55. PubMed ID: 10585299
    [Abstract] [Full Text] [Related]

  • 12. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
    Pharm Unserer Zeit; 1997 Dec 22; 26(6):317. PubMed ID: 9513575
    [No Abstract] [Full Text] [Related]

  • 13. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R, Chiodo F.
    J Infect; 2001 Apr 22; 42(3):181-8. PubMed ID: 11545549
    [Abstract] [Full Text] [Related]

  • 14. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov 22; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 15. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X, Podzamczer D, Moral I, Roset M, Arnaiz JA, Loncà M, Casiró A, Rosón B, Gatell JM, BestQol Study Group.
    Antivir Ther; 2004 Dec 22; 9(6):979-85. PubMed ID: 15651756
    [Abstract] [Full Text] [Related]

  • 16. Saquinavir soft-gel capsule: an updated review of its use in the management of HIV infection.
    Figgitt DP, Plosker GL.
    Drugs; 2000 Aug 22; 60(2):481-516. PubMed ID: 10983742
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J.
    Antivir Ther; 2003 Dec 22; 8(6):595-602. PubMed ID: 14760893
    [Abstract] [Full Text] [Related]

  • 18. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 22; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 19. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M, van der Ende ME.
    Antivir Ther; 2003 Oct 22; 8(5):455-61. PubMed ID: 14640393
    [Abstract] [Full Text] [Related]

  • 20. [Adherence to antiretroviral treatments with a protease inhibitor in HIV-infected patients].
    Salmon-Céron D, Deleuze J, Coste J, Guerin C, Ginsburg C, Blanche P, Finkielsztejn L, Pecqueux L, Chaput S, Gorin I, Sicard D.
    Ann Med Interne (Paris); 2000 Jun 22; 151(4):297-302. PubMed ID: 10922958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.